SUMO2

A gene on chromosome 17q25.1 that encodes a broadly expressed ubiquitin-like protein, which can be covalently attached to proteins as a monomer or a lysine-linked polymer. This post-translational modification on lysine residues of protein (sumolyation) plays a crucial role in a number of cellular processes, including nuclear transport, DNA replication and repair, mitosis and signal transduction. SUMO2 interacts with PELP1, SAE2 and USP25; it is activated when its precursor form is cleaved by SENP1 or SENP2.

Mentioned in ?

References in periodicals archive ?

Previous research revealed that PIASy preferentially stimulates site-selective modification of IKK[gamma] by SUMO1, but not SUMO2 and SUMO3, in vitro.

SUMO E3 Ligase PIASy Mediates High Glucose-Induced Activation of NF-[kappa]B Inflammatory Signaling in Rat Mesangial Cells

The design of a multiple drug combination for treating stage 1 bladder cancer depends on a strategy of inhibiting the highly expressed genes ADRM1, COPS5, PSMD8, SUMO2, CALR, PDIA3, DNAJB11, HSPA5, RPN1, CUL1, HSP90B1, KPNA2, PSMD12, ECT2, TK1, TUBA1C, HN1, and ENO1; activating the suppressed genes UBC, JUN, RARRES3, and FOS; and suppressing the drug's effect on the nondifferentially expressed genes BAG6, HUWE1, PAAF1, PSMD10, FAF2, PCYT1A, and PSMD10.

The design of a multiple drug combination for treating stage 4 bladder cancer depends on a strategy of inhibiting the highly expressed genes ADRM1, COPS5, PSMD8, SUMO2, RNF126, CALR, PDIA3, DNAJB11, HSPA5, RPN1, HSP90AA1, HSPA1B, METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1; activating the suppressed genes BCL3, FOS, UBC, and GTF2A1; and suppressing the drug's effect on the nondifferentially expressed genes, which are the same as those in stage 1 bladder cancer.

Network biomarkers of bladder cancer based on a genome-wide genetic and epigenetic network derived from next-generation sequencing data

A comprehensive analysis led scientists to two specific genes, Chaf1a and Sumo2, that are the key factors linked to proviral silencing.

Further studies on the roles of Chaf1a and Sumo2 in stem cell proviral silencing can shed new light on stem cells and virus biology that could translate into valuable therapeutic and diagnostic applications.

How stem cells defend against viruses

Through a comprehensive analysis, the scientists concluded that two specific genes, Chaf1a and Sumo2, are the key factors linked to proviral silencing.